Investor Presentaiton

CASE STUDIES: INVESTMENT PROJECTS IN 2018-2019 Servier, GSK/ViiV Healthcare V SERVIER AEB Association of European Businesses CEO Jérôme GAVET, Managing Director of Servier Group for Russia and EAEU Xavier MORELON, General Manager of pharmaceutical plant "Servier RUS" Oleg DUBYANSKIY, General Director, GlaxoSmithKline Date of the investment project 25 April 2019 Location Moscow Brief information about the investment project On 25 April 2019 local manufacturing of the innovative anti- HIV drug was launched in Moscow at Servier RUS produc- tion site in partnership with GSK/ViiV Healthcare. This part- nership for contract manufacturing is significant for the local market - it will improve access of the drug to people. Project progress The decision on the need to manufacture the drug locally in Russia was made in 2015, less than a year after the regis- tration. The agreement between the drug's developer ViiV Healthcare and Servier, which has its own pharmaceutical plant in Russia (Servier RUS plant), was signed in May 2016. The design of the localization project involves the one-stage start of production of a full cycle (production of a finished dosage form) without intermediate steps, such as secondary packaging. In September 2016, the first pilot and registration series of the drug were produced at Servier RUS production complex located in New Moscow. During 2017, ViiV Healthcare and GSK (Great Britain) and Sh- ionogi (Japan) production sites, which were included in the technology transfer process, were inspected and received Russian GMP certificates. In 2018, a pharmaceutical substance was registered in Rus- sia, and Servier pharmaceutical plant was approved (regis- tered) by the Ministry of Health of the Russian Federation as the Russian production site for the drug. In the same year, within the framework of the St. Petersburg International Eco- nomic Forum, GSK and Servier signed a final agreement on the launch of full-scale manufacturing in Russia. The agreement on production is for a period of 5 years with plans to extend. The flexible scope of the production plan provided by the agreement will satisfy the demand for this drug in Russia. In 2019, a high-tech line for the drug's production, which has no analogues in Russia, was installed at the Servier RUS plant. Servier is one of the active participants in the current state pilot labeling project for drugs, and the new equipment fully complies with Russian regulatory requirements. The official opening ceremony of the production line took place on April 25, 2019. The implementation of the agreement will ensure the avail- ability of a key innovative drug for the treatment of HIV infec- tion produced in Russia, which will contribute to achieving the goals of combating the spread of HIV infection, as well as contribute to the development of the Russian pharmaceutical industry and the innovative potential of Moscow. 10

View entire presentation